

& Number	Date Effective
CAR-T Medications - Tecartus - OH MP - MM-1095	07/01/2022-11/30/2022
Policy Type	
MEDICAL	

Table of Contents

A. Subject.....2

B. Background.....2

C. Definitions2

D. Policy2

E. Conditions of Coverage.....3

ARE

A. Subject

CAR-T Medications – Tecartus (brexucabtagene autoleucel)

B. Background

Chimeric antigen receptor T-cell therapy (CAR-T) is an autologous T-cell immunotherapy. The patient's own T lymphocytes are genetically modified with a gene

Archived



3.

Archived

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.



G. Review/Revision History

	DATE	ACTION
Date Issued	04/14/2021	
Date Revised	02/07/2022	Updated definitions. Added criteria for acute lymphoblastic

Archived

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.